NICE (UK) terminated appraisal for Tevimbra (tislelizumab) in combination for untreated advanced non-small-cell lung cancer – BeiGene

NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults.

This is because the company did not provide an evidence submission.

The company has confirmed that it does not intend to make a submission for the appraisal because the technology will not be launched in the UK for this indication.